Diabetes News

In patients with obesity and heart disease, semaglutide 2.4 mg reduced risk for major adverse cardiovascular events regardless of baseline kidney function, according to new data from the SELECT trial.

Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial.

Adults with type 2 diabetes at high risk for cardiovascular events were more likely to sustain an HbA1c of 6.5% or less at 2 years with tirzepatide if they lost more weight and had improved beta-cell function, according to new data.

The Cardiometabolic Health Congress announced that Peter Libby, MD, one of the foremost authorities in atherosclerosis, will deliver the keynote address at its upcoming 19th annual conference.

Women with fetal overgrowth or hypertensive disorders of pregnancy have notable continuous glucose monitor-derived glycemic patterns detected during early pregnancy, sometimes without a gestational diabetes diagnosis, researchers reported.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.

Discontinuation of renin-angiotensin system inhibitor therapy before major noncardiac surgery did not appear to affect postoperative outcomes vs. treatment continuation, a speaker reported.

Researchers estimate that semaglutide 2.4 mg is not cost-effective for secondary CVD prevention for patients with overweight or obesity without diabetes, according to an Australian study.